The purpose of this study was to determine the incidence of prostate cancer in patients who have an elevated referral prostate-specific antigen (PSA), which subsequently falls to within their normal age-specific reference range prior to prostate biopsy. The study demonstrated that of the 160 patients recruited, 21 (13%) had a repeat PSA level which had fallen back to within their normal range. Five of these 21 patients (24%) were diagnosed with prostate cancer following biopsy, two of whom had a benign prostate examination. The study, therefore, demonstrates that normalisation of the PSA level prior to biopsy does not exclude the presence of prostate cancer even when the prostate feels benign.
Introduction
Patients with an elevated prostate-specific antigen (PSA) level are known to have an increased risk of harbouring prostate cancer. 1 However, recent work by Eastham et al. 2 has shown that a significant proportion of patients found to have an elevated PSA, will have a normal value if it is repeated. In their study, Eastham et al 2 investigated the year-to-year fluctuations that occur with PSA readings and reported that these fluctuations render a single PSA test unreliable. Their study involved a retrospective analysis of 972 men who had participated in a Polyp Prevention Trial between 1991 and 1998. Patients had undergone five consecutive PSA tests during their 4-y follow-up. The group found that between 15 and 37% of the study patients, depending on the cutoff used would have been referred for a prostate biopsy due to an abnormal PSA reading, at some point during their 4-y follow-up. However, 40-55% of these men had at least one normal PSA reading during the study period. The group, therefore, concluded that an isolated PSA level is unreliable and should be confirmed before proceeding with a biopsy. Although this study clearly demonstrates the impact that PSA variability can have on the clinical decisions made, it does not indicate the significance of such PSA changes, and in particular the individuals risk of having prostate cancer.
Singh et al 3 recently suggested that patients who normalise their PSA in this way are not at risk of having clinically significant prostate cancer, providing their prostate feels benign. 3 This conclusion was made after studying men with an elevated PSA level (less than 50 ng/ml) according to age-specific reference ranges. The patients, all of whom underwent repeat PSA testing only underwent a biopsy if the repeat test remained elevated or the prostate examination was suspicious of malignancy. Of the 101 men who were recruited into the study, 35 had a repeat PSA test, which had normalised. Three of these 35 patients had an abnormal DRE and underwent a biopsy following which all three were diagnosed with cancer. Of the 32 cases who had a normalised repeat PSA and a non-malignant prostate examination, 28 were available for follow-up at 2 y. In 23 of these 28 patients the PSA level had remained within the normal range. The group, therefore, concluded that a biopsy can be safely avoided in those men who despite an initially elevated PSA have a repeat level which lies within their age-specific reference range, if these patients have a nonmalignant prostate examination. However, neither this study nor that by Eastham et al 2 performed a prostate biopsy and the presence of prostate cancer could not, therefore, be confidently excluded in their patients.
The current study therefore addresses the clinical significance of a PSA level, which returns to within the normal range prior to biopsy, in terms of the risk of underlying prostate cancer. All patients had a referral PSA level, which was compared to a repeat test taken prior to prostatic biopsy and the subsequent histology.
Materials and methods
Following approval from the local ethics committee the study group was recruited from patients attending the transrectal ultrasound (TRUS) guided biopsy clinic between February 2003 and February 2004. The majority of patients were referred directly by their general practitioner (GP), although in a few cases the referral was made by a member of the urology team following assessment in the outpatient department. All patients were invited to participate in the study if they met the following inclusion criteria.
Referral PSA above their age-specific cutoff (40-49 y 0-2.5 ng/ml, 50-59 y 0-3.5 ng/ml, 60-69 y 0-4 ng/ml, 70-79 y 0-6.5 ng/ml): A full urological history was obtained from all patients to elicit any infections and to record the following details: reason for PSA testing/referral, history of previous prostate operations and history of cystoscopy within the previous 12 months. The TRUS biopsy policy in this department is not to biopsy patients in whom it is felt that their elevated PSA may be due to a urinary tract infection until it is clear that it has failed to normalise with the passage of time.
If the urological history confirmed the need for prostatic biopsy study patients were asked to give a blood sample for repeated PSA testing followed by a digital rectal examination (DRE) of the prostate. Patients then underwent an 8-10 core biopsy targeting the lateral and apical areas of the peripheral zone if clinically indicated.
Data analysis compared the referral and repeat PSA value in light of the subsequent histology. Statistical analysis was performed on the repeat PSA values to detect whether the observed change in values was significantly greater than might have been observed through natural physiological variation.
All patients referred to the TRUS biopsy clinic were from GP surgeries, which use the biochemistry laboratory at the Royal Berkshire Hospital for their PSA testing. The same laboratory was used for the repeat test. The mean coefficient of variation for the Centaur assay used in this laboratory was 5.3%.
Results
In all, 160 patients were recruited into the study, 13% (21) of whom had a repeat PSA value within their normal age-specific reference range. The demographic details for the study group as whole and those patients who did and did not normalise their PSA are presented in Table 1 .
In the absence of a formal screening programme we found it impossible to distinguish accurately between patients who were referred for biopsy as a result of lower urinary tract symptoms (LUTS) and those where it was performed as part of a screening programme, as in many patients it was the development of LUTS that resulted in the initial visit to their GP. Table 2 shows the original reason for PSA testing/referral in the study patients. The LUTS and screening patients are categorised into one group.
In total, 83 of the 160 (52%) study patients were diagnosed with prostate cancer. Of these 83 patients, 20 (24%) had a normal prostate examination prior to biopsy. Of the 139 patients who had a repeat PSA, which remained elevated, 78 (56%) were diagnosed with prostate cancer, 18 (23%) of whom had a normal DRE. The remaining 60 (77%) patients were felt to have a prostate suspicious for malignancy on examination. Figure 1 presents the number of patients with cancer or high-grade precursor intraepithelial neoplasia (HGPIN)/ suspicious histology in both the patients who normalised their PSA and those who did not. The number of these patients recorded as having a benign feeling prostate before the biopsy is also presented.
There were five cases of prostate cancer diagnosed in the 21 patients who demonstrated a normalised PSA. In two of these cases the DRE prior to the biopsy had been recorded as benign. Both of these cancers were Gleason pattern 3 þ 3 disease in a single core. One of these patients subsequently underwent brachytherapy with no complications, and the other opted for a 'watch and pounce' policy for which no further intervention has been required to date. There were three additional cases of cancer diagnosed in the 21 patients who demonstrated a normalised PSA, all had a suspicious DRE recorded prior to the biopsy. In one of these cases there was again evidence of Gleason pattern 3 þ 3 disease in a single core. However, in the other two cases, one had Gleason 3 þ 4 disease in all four cores of one lobe and the second had two small areas of invasive Gleason 4 þ 3 disease associated with HGPIN.
There were also three patients in this group who had HGPIN or suspicious pathology on histological analysis. All three of these patients had a benign prostate examination prior to the procedure. One patient has not undergone a repeat biopsy to date, but of the two that have, one had benign histology and the other was confirmed to have HGPIN.
Significance of the drop in PSA level
Patients with a baseline PSA level, which lies just above their age-specific cutoff range, will demonstrate intermittent 'normalisation' of their PSA level as a consequence of normal physiological variation. A previous study conducted by this group reported the coefficient of variation to be in the order of 10% 4 and others give figures of 15%. 5 The current study used the value of 10% to determine the number of patients who had a fall in their PSA level, which was greater than would be expected through normal PSA variation. For each patient a critical value was calculated, above which the reduction would be considered to be significant. This critical value, which took into account both the referral and repeat PSA value for each patient, used a 5% risk setting and the assumption of a coefficient of variation of 10%. 4 The results demonstrated that 45 of the 69 patients whose repeat PSA remained elevated, but which had fallen, demonstrated a reduction in their PSA, which was within the normal limits of physiological variation. Only 24 of these 69 demonstrated a significant drop in their PSA. This is in contrast to the group of patients who had a repeat PSA that had fallen to within their normal range. In this group, 18 of the 21 patients demonstrated a significant drop in the PSA level, (Figure 2 ). This finding suggests that the patients who 'normalised' their PSA were not simply those with PSA levels on the upper limit of their normal age-specific cutoff range demonstrating normal degrees of variation. Instead these patients had significant reductions in their PSA level. All five of the patients diagnosed with prostate cancer in the group who had a normal repeat PSA level, demonstrated a significant drop in their PSA.
Discussion
PSA is commonly reported as being the most useful oncological marker in clinical practice. However, it is not without its limitations, most notably its lack of specificity for prostate cancer and its inherent variability. Recent work has shown that a significant proportion of patients found to have an elevated PSA, will have a normal value if it is repeated. 2 What is uncertain, however, is how this relates to the presence of prostate cancer. In order to answer this question, this study investigated a group of men referred for prostatic biopsy on the basis of an elevated PSA level. A repeat PSA test taken immediately prior to biopsy was then compared to both the referral PSA value and subsequent histology.
The study found that 21 of the 160 (13%) patients referred with an elevated PSA had on repeat testing a PSA level, which was within their age-specific reference range. The demographic data and reasons for referral, as shown in Table 1 , indicate that there were no significant differences in age and referral PSA between these two groups. Likewise, the presence of confounding factors, such as recent cystoscopy, were not found to have affected the study results. However, the careful attempt to exclude patients with urinary tract infections, may account for why fewer patients in this study normalised their PSA (21 of 160) when compared to that by Singh et al 3 PSA normalisation and prostate cancer JL Boddy et al suspected on DRE before the procedure in 77% of cases. There were five cases of cancer diagnosed in the 21 patients whose PSA fell to within their normal reference range. If the protocol of not performing a biopsy in those patients who had a normal DRE and a normal PSA on repeat testing had been employed there would have been two missed cases of cancer. Both of these cases were Gleason pattern 3 disease in a single core and it could be argued that these cases may not prove to be of clinical significance. However, it is not possible to ensure that these cancers will not progress and, as such, it could equally be argued that it is better to know that prostate cancer is present, even if it is of low grade and stage, to enable adequate monitoring although the impact of diagnosing such cancers on patients' wellbeing must not be forgotten. There were three further patients diagnosed with cancer, all of whom had a suspicious DRE prior to biopsy. These cancers were, however, of greater clinical significance with one case having Gleason 4 þ 3 disease. All three of these cancer patients were classified as having a suspicious DRE by a physician trained in this procedure. However, if these examinations had been performed by less experienced staff, some may have been recorded as benign and this could have resulted in these cancers remaining undiagnosed. If it is proposed that a biopsy can be avoided in patients where an elevated PSA returns to within the age-specific reference range before the biopsy, assuming a normal feeling prostate, it becomes essential for an experienced member of staff to perform the DRE examination. This has particular implications in general practice, where all GPs without sufficient urological experience, would have to be encouraged to refer any patients who had an elevated PSA, even if it then returns to within that patients normal reference range, for a specialist opinion.
The ranges used in this study had an upper limit of 4.0 ng/ml for men aged 60-69 y, however, the upper limit of 4.5 ng/ml is also commonly used for this age group. If this upper limit had been used instead for men aged 60-69 y, 23 patients would have normalised their PSA. This would have meant two further cases of potentially missed prostate cancer, one where the DRE had been recorded as suspicious (bilateral Gleason 3 þ 3) and another where the prostate examination felt benign (single focus of Gleason pattern 3/5).
Thompson et al 6 recently demonstrated that biopsydetected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng/ml or less, levels generally thought to be within the normal range. This study could, therefore, simply be demonstrating this finding. However, this study clearly demonstrates that not only can prostate cancer be detected in patients with a normal PSA level but that this PSA level is not static and can rise and fall by levels greater than would be expected through normal PSA variation alone. Only 24 of the 69 (35%) study patients who had a fall in their PSA value, but not to within their normal range, demonstrated a significant drop, whereas this increased to 86% (18 of 21) in those where the repeat PSA level had drop to within the normal age-specific reference range. In particular, all five of the cancer cases diagnosed in the group whose PSA fell to within their normal range demonstrated a significant drop in their PSA level. The reasons for these significant changes in the PSA are not clear. Stamey et al 7 recently reported that benign prostatic hypertrophy (BPH) is likely to account for much of the elevated PSA for levels between 2 and 9 ng/ml. It is possible, therefore, that the changes seen in the PSA levels are purely a reflection of minor degrees of inflammation within the prostate that are unrelated to the presence of prostate cancer. These cancers may be being picked up as a consequence of these incidental changes in the PSA level. Regardless of the cause what this study demonstrates is that the extent of the fall in PSA cannot be used to rule out the diagnosis of prostate cancer.
Conclusions
Should the PSA level be repeated in all patients before they undergo an initial prostate biopsy, as recommended by Eastham et al 2 ? This study found five cases of cancer in those patients who demonstrated PSA normalisation prior to biopsy, two of whom had a benign prostate examination. Although this is only a small number it clearly demonstrates that 'normalisation' of the PSA level before the biopsy procedure does not exclude the presence of prostate cancer. In addition if the proposal is to repeat all elevated PSA findings, as some will normalise, it also becomes logical to repeat all normal PSA tests, as by the same virtue some of these will become abnormal. Given the significant financial implications of repeating all initial PSA tests, it is essential that we first fully understand how such a recommendation will effect the number of prostate cancers diagnosed and of equal importance the types of cancer detected, before it can be endorsed.
